^
Association details:
| Biomarker: | FGF3 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma†
Excerpt:
A 58‐year‐old woman was diagnosed as having histologically confirmed advanced HCC...She received combination treatment with sorafenib, 5‐fluorouracil (5FU), and interferon, and a subsequent treatment assessment revealed a partial response. Because the disease was well controlled with sorafenib treatment for 14 months...FGF3 was overexpressed in the HCC specimen compared with the paired background liver specimen...
Secondary therapy:
5-fluorouracil
DOI:
https://doi.org/10.1002/hep.25956
